Payment overview · 2025
General Payments
$1,056.54
46 reported records · 13 companies
Healthcare provider profile · identity verified
Patrick Devincent Moore, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LAFAYETTE, LA · NPI 1982604419
Verified facts
What the public records show
CMS Open Payments records show Patrick Devincent Moore, M.D. received $1,056.54 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Farxiga, Furoscix, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 378 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
SCPHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FUROSCIX as an associated drug or biological on 18968 records involving 9678 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Furoscix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.15 | 19.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $188.17 | 17.8% | 12 | 2025 |
| Zynex Medical, Inc. | Unresolved — no canonical attribution shown | $139.82 | 13.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $136.54 | 12.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.66 | 8.1% | 4 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $78.33 | 7.4% | 4 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $49.66 | 4.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.85 | 4.4% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.70 | 4.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.33 | 2.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.91 | 2.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.90 | 1.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.52 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,056.54 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $188.17 | 12 | 2025 |
Source payment records
|
|||||
| Nexwave Normalized: nexwave |
Device | Zynex Medical, Inc. | $139.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $136.54 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $132.76 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $85.66 | 4 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $78.33 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $70.39 | 4 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $49.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.85 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.70 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $46.63 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.79 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
| FUROSCIX furoscix |
2025 | Furoscix | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 378 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 192 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 23 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
192 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
174 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
378 | 75 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
122 | 29 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SCPHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | FUROSCIX open payments reported associated product |
CMS Open Payments — General Payments 18968 supporting records · 9678 recipient NPIs · example record 1228171755 |
Furoscix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 583 | 173 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 531 | 155 |
| Mounjaro | Tirzepatide | 378 | 75 |
| Irbesartan | Irbesartan | 333 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 99 |
| Metformin Hcl Er | Metformin Hcl | 237 | 64 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 192 | 67 |
| Vascepa | Icosapent Ethyl | 192 | 63 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 182 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 55 |
| Pioglitazone Hcl | Pioglitazone Hcl | 177 | 54 |
| Jardiance | Empagliflozin | 174 | 44 |
| Tradjenta | Linagliptin | 151 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 39 |
| Pregabalin | Pregabalin | 124 | 35 |
| Trulicity | Dulaglutide | 122 | 29 |
| Allopurinol | Allopurinol | 117 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 32 |
| Furosemide | Furosemide | 103 | 35 |
| Carvedilol | Carvedilol | 100 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 93 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 90 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 24 |
| Gabapentin | Gabapentin | 85 | 27 |
| Linzess | Linaclotide | 85 | 27 |
| Farxiga | Dapagliflozin Propanediol | 75 | 23 |
| Finasteride | Finasteride | 74 | 17 |
| Meloxicam | Meloxicam | 72 | 24 |
| Montelukast Sodium | Montelukast Sodium | 71 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 48 |
| Potassium Chloride | Potassium Chloride | 67 | 17 |
| Alprazolam | Alprazolam | 65 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 19 |
| Ozempic | Semaglutide | 60 | 14 |
| Tramadol Hcl | Tramadol Hcl | 60 | 15 |
| Xarelto | Rivaroxaban | 59 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 20 |
| Famotidine | Famotidine | 58 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 19 |
| Lisinopril | Lisinopril | 55 | 13 |
| Topiramate | Topiramate | 53 | 26 |
| Niacin Er | Niacin | 51 | 13 |
| Repatha Syringe | Evolocumab | 50 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 47 | 15 |
| Armour Thyroid | Thyroid,pork | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 18 |
| Metolazone | Metolazone | 41 | suppressed |
| Omeprazole | Omeprazole | 41 | 14 |
| Meclizine Hcl | Meclizine Hcl | 40 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 38 | 31 |
| Prednisone | Prednisone | 37 | 30 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | 11 |
| Sucralfate | Sucralfate | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | 16 |
| Diazepam | Diazepam | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 25 |
| Losartan Potassium | Losartan Potassium | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 13 |
| Valsartan | Valsartan | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | 12 |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Repatha Pushtronex | Evolocumab | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 14 |
| Lacosamide | Lacosamide | 14 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Furoscix | Furosemide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,056.54 · 46 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, COMIRNATY, Dexcom G6 Transmitter, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, FARXIGA, FUROSCIX, Korlym, LEQVIO, MOUNJARO, NEXLETOL, Nexwave, OTEZLA, Ozempic, PREVNAR 20, REPATHA, TRELEGY ELLIPTA, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error